Clinical Trial Update: Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating gemcitabine hydrochloride alone or in combination with M6620 for recurrent ovarian, fallopian tube, or primary peritoneal canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• M6620 (VX-970) (VX-970)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-10-25